Form 8-K - Current report:
SEC Accession No. 0001193125-24-258757
Filing Date
2024-11-14
Accepted
2024-11-14 17:00:54
Documents
15
Period of Report
2024-11-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d889360d8k.htm   iXBRL 8-K 31692
2 EX-4.1 d889360dex41.htm EX-4.1 84561
3 EX-10.1 d889360dex101.htm EX-10.1 215710
  Complete submission text file 0001193125-24-258757.txt   536138

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vcnx-20241113.xsd EX-101.SCH 2842
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vcnx-20241113_lab.xml EX-101.LAB 17236
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vcnx-20241113_pre.xml EX-101.PRE 10807
18 EXTRACTED XBRL INSTANCE DOCUMENT d889360d8k_htm.xml XML 3533
Mailing Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620
Business Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620 585-271-2700
VACCINEX, INC. (Filer) CIK: 0001205922 (see all company filings)

EIN.: 161603202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38624 | Film No.: 241463986
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)